Letermovir for prevention of recurrent CMV in high-risk allogeneic hematopoietic cell transplant (HCT) recipients.
Han G, Stern A, Lee YJ, Li Y, Dahi PB, Tamari R, Gyurkocza B, Jakubowski AA, Papadopoulos EB, Shaffer B, Perales MA, Obeid KM, Young JH, Papanicolaou GA.
Han G, et al. Among authors: lee yj.
Transplant Cell Ther. 2024 Dec 17:S2666-6367(24)00811-X. doi: 10.1016/j.jtct.2024.12.010. Online ahead of print.
Transplant Cell Ther. 2024.
PMID: 39701288